Primecap Management’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-328,100
| Closed | -$755K | – | 332 |
|
|
2023
Q2 | $755K | Sell |
328,100
-17,800
| -5% | -$46.3K | ﹤0.01% | 318 |
|
|
2023
Q1 | $1.05M | Sell |
345,900
-5,600
| -2% | -$15.8K | ﹤0.01% | 311 |
|
|
2022
Q4 | $819K | Sell |
351,500
-71,800
| -17% | -$172K | ﹤0.01% | 320 |
|
|
2022
Q3 | $809K | Hold |
423,300
| – | – | ﹤0.01% | 321 |
|
|
2022
Q2 | $1.15M | Sell |
423,300
-37,700
| -8% | -$96.5K | ﹤0.01% | 318 |
|
|
2022
Q1 | $1.37M | Sell |
461,000
-9,000
| -2% | -$27.6K | ﹤0.01% | 322 |
|
|
2021
Q4 | $1.83M | Sell |
470,000
-30,000
| -6% | -$117K | ﹤0.01% | 317 |
|
|
2021
Q3 | $2.15M | Hold |
500,000
| – | – | ﹤0.01% | 314 |
|
|
2021
Q2 | $1.51M | Hold |
500,000
| – | – | ﹤0.01% | 320 |
|
|
2021
Q1 | $1.67M | Hold |
500,000
| – | – | ﹤0.01% | 312 |
|
|
2020
Q4 | $1.77M | Hold |
500,000
| – | – | ﹤0.01% | 303 |
|
|
2020
Q3 | $1.56M | Hold |
500,000
| – | – | ﹤0.01% | 292 |
|
|
2020
Q2 | $910K | Sell |
500,000
-80,100
| -14% | -$131K | ﹤0.01% | 295 |
|
|
2020
Q1 | $586K | Sell |
580,100
-19,900
| -3% | -$53.8K | ﹤0.01% | 282 |
|
|
2019
Q4 | $1.67M | Sell |
600,000
-3,440,900
| -85% | -$5.57M | ﹤0.01% | 281 |
|
|
2019
Q3 | $6.16M | Hold |
4,040,900
| – | – | ﹤0.01% | 244 |
|
|
2019
Q2 | $8.4M | Hold |
4,040,900
| – | – | 0.01% | 246 |
|
|
2019
Q1 | $14.5M | Hold |
4,040,900
| – | – | 0.01% | 225 |
|
|
2018
Q4 | $15.5M | Sell |
4,040,900
-29,500
| -0.7% | -$145K | 0.01% | 218 |
|
|
2018
Q3 | $38.5M | Buy |
4,070,400
+70,000
| +2% | +$695K | 0.03% | 199 |
|
|
2018
Q2 | $29.2M | Hold |
4,000,400
| – | – | 0.02% | 203 |
|
|
2018
Q1 | $20M | Hold |
4,000,400
| – | – | 0.02% | 213 |
|
|
2017
Q4 | $20.2M | Buy |
4,000,400
+10,000
| +0.3% | +$58.6K | 0.02% | 210 |
|
|
2017
Q3 | $24.7M | Buy |
3,990,400
+40,000
| +1% | +$171K | 0.02% | 196 |
|
|
2017
Q2 | $14.2M | Buy |
3,950,400
+10,000
| +0.3% | +$34.4K | 0.01% | 220 |
|
|
2017
Q1 | $12.8M | Buy |
3,940,400
+5,400
| +0.1% | +$15K | 0.01% | 216 |
|
|
2016
Q4 | $9.64M | Buy |
3,935,000
+65,200
| +2% | +$190K | 0.01% | 225 |
|
|
2016
Q3 | $13.3M | Buy |
3,869,800
+19,800
| +0.5% | +$77.4K | 0.01% | 214 |
|
|
2016
Q2 | $13.4M | Hold |
3,850,000
| – | – | 0.01% | 216 |
|
|
2016
Q1 | $15.9M | Buy |
3,850,000
+919,018
| +31% | +$3.28M | 0.02% | 208 |
|
|
2015
Q4 | $13M | Buy |
2,930,982
+92,982
| +3% | +$510K | 0.01% | 212 |
|
|
2015
Q3 | $17.3M | Buy |
2,838,000
+758,000
| +36% | +$6.72M | 0.02% | 198 |
|
|
2015
Q2 | $24.7M | Buy |
2,080,000
+1,531,397
| +279% | +$23.3M | 0.02% | 194 |
|
|
2015
Q1 | $9.58M | Buy |
+548,603
| New | +$11.2M | 0.01% | 222 |
|
Other funds holding ABUS
WCM
TSC
WP
Primecap Management's ABUS Position: Q3 2023 in Review
Primecap Management sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 328,100 shares — an estimated $755K sold.
Primecap Management first reported a position in ABUS in Q1 2015 and held it in 34 quarters. The position peaked at $38.5M in Q3 2018. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.
- Primecap Management reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
- Primecap Management sold 328,100 Arbutus Biopharma shares in Q3 2023, an estimated $755K.
- Primecap Management first reported a position in Arbutus Biopharma in Q1 2015 and held it in 34 quarters.
- Primecap Management's Arbutus Biopharma position peaked at $38.5M in Q3 2018.
- 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.
Based on Primecap Management's 13F filing for Q3 2023, filed 13 Nov 2023.